Motion activated septum puncturing drug delivery device

Information

  • Patent Grant
  • 9878091
  • Patent Number
    9,878,091
  • Date Filed
    Monday, April 27, 2015
    9 years ago
  • Date Issued
    Tuesday, January 30, 2018
    6 years ago
Abstract
A method and apparatus are disclosed for delivery of a drug to a recipient. In some embodiments, the delivery apparatus may unseal a drug containing reservoir. In some embodiments, the delivery rate may be controlled and/or adjustable. Optionally the apparatus may be disposable. Optionally, the apparatus may have a low profile and/or be wearable and/or attachable to the recipient. Optionally, discharge of the drug and/or unsealing of the reservoir may be driven by a plunger moving parallel to the base of the apparatus. Optionally, the apparatus may release a hypodermic needle into the recipient. Optionally, release of the hypodermic needle may be in a direction non-parallel and/or orthogonal to the direction of movement of the plunger. Optionally, prior to release, the hypodermic needle may be preserved in an aseptic state by a needle opening septum sealing a needle opening. Optionally, upon release, the hypodermic needle may pierce the needle opening septum.
Description
BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to an apparatus wearable by a recipient and method for delivering a substance to a recipient, more particularly, but not exclusively, to an apparatus with a single-motion controlled-rate power train for sequentially unsealing a reservoir containing a drug and delivering the drug to a recipient.


U.S. Published Patent Application 2009/0093792 to the present author discloses an apparatus for administering a substance to a subject. A vial contains the substance and a stopper is disposed within the vial and is slidably coupled to the vial. A first threaded element is (a) rotatable with respect to the vial and (b) substantially immobile proximally with respect to the vial during rotation of the first threaded element. A second threaded element is threadedly coupled to the first threaded element. At least a distal end of the second threaded element is substantially non-rotatable with respect to the vial, and the distal end of the second threaded element defines a coupling portion that couples the second threaded element to the stopper. The first threaded element, by rotating, linearly advances the stopper and at least the distal end of the second threaded element toward a distal end of the vial. A vial piercing mechanism is movably (e.g., rotatably) coupled to a housing base. As part of the insertion of vial into the housing base, a seal at distal end of the vial is pierced by pressing the seal against the piercing mechanism. The substance is configured to subsequently flow through a tube toward an activation mechanism, which is typically coupled to the housing base, and is configured to insert a cannula and/or a needle through the subject's skin and to deliver the substance via the cannula and/or the needle.


U.S. Pat. No. 5,858,001 to Tsals discloses a liquid drug delivery device adapted to be adhered to the skin of a subject by a base member defining a skin-contacting surface having an adhesive coating. A columnar cartridge serves as reservoir for the drug and is incorporated in a housing which is connected to the base member such that in use the longitudinal axis of the cartridge is disposed substantially parallel to the skin-contacting surface. A delivery needle communicating in use with the interior of the cartridge penetrates the skin of the subject when the housing snaps downward relative to the base member. This action also causes the actuation of a citric acid/sodium bicarbonate gas generator which generates a gas to move a piston within the cartridge, compressing the drug compartment. This compression causes a stopper to be penetrated by a conduit in communication with the delivery needle, allowing the drug to be ejected from the compartment through the needle and into the subcutaneous tissue of the subject.


US Published Patent Application 2006/0173408 to Wyrick discloses a reloadable medicine injector and methods in which a barrel with a receiving cavity is adapted to slidably to receive a syringe subassembly for axial movement therein. Upon removal of a safety and release of a syringe driver, the syringe driver moves forward and injects the syringe needle. A plurality of penetration controls are shown for controlling injection needle penetration depth. In some embodiments, the injector makes use of a double needle assembly in which a double needle hub mounts a seal penetration needle that projects rearwardly toward a penetrable seal on the associated ampule. A flesh penetration needle projects forwardly. In practice, both needles can be made integral.


U.S. Pat. No. 5,997,501 to Gross discloses an intradermal drug delivery device comprising a housing having a drug reservoir therewithin. A microprocessor-controlled electrolytic cell provides gas to expand a gas generation chamber and thereby contract the reservoir. A hollow needle, communicating at an inner end thereof with the reservoir, extends from a lower surface of the housing such that contraction of the reservoir forces drug to escape therefrom via the needle. The device permits delivery of drugs of relatively large molecular weights at slow rates.


U.S. Published Patent Application 2011/0178472 and PCT Application WO 2011/090955 to the present author disclose a needle assembly adapted for fluid communication with a cartridge containing a substance to be delivered to a subject. The needle assembly characterized by a biasing device arranged to apply a biasing force on a needle to cause the needle to protrude outwards of a housing to pierce the subject, and biasing device release apparatus including a biasing device arrestor that initially blocks movement of the biasing device. After finishing the drug administration, the needle release apparatus lifted off the patient's body, which causes the safety latch to move back to the down position and the needle to be retracted back into the housing.


A safety latch position sensor is provided for sensing when safety latch moves to an up position indicating that the device has been attached to a patient. A controller initiates operation of an actuator after a predetermined time delay (e.g., 5-15 seconds) to ensure that the drug delivery apparatus was indeed placed on purpose on the patient for delivering the drug. When operated, the actuator rotates a shaft causing the biasing device arrestor to move linearly out of an aperture. As soon as the biasing device arrestor has moved out of the aperture, the biasing device is no longer blocked and it now pushes down on a needle piercing the patient's skin.


Additional background art includes U.S. Published Patent Applications 2011/0178472 to the same author, U.S. Pat. No. 7,789,862 to Thorne, U.S. Pat. No. 7,780,636 to Radmer, U.S. Pat. No. 5,957,895 to Sage, U.S. Pat. No. 7,918,843 to Genosar, and U.S. Pat. No. 7,789,862 to Thorne.


BRIEF SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided an apparatus wearable by a recipient having a single motion power train for sequentially unsealing a reservoir and delivering a drug to the recipient. The apparatus may include a seal of the reservoir. The apparatus may also include a controlled rate power source. The apparatus may also include a plunger driven by the controlled rate power source. The apparatus may also include a hollow needle. An initial movement of the plunger may drive the hollow needle through the seal and subsequent movement of the plunger may discharge the drug from the reservoir.


According to some embodiments of the invention, the controlled rate power source may include a direct current motor, a stepper motor and/or a linear actuator.


According to some embodiments of the invention, the apparatus may further include a surface configured for attaching to a skin of the recipient.


According to some embodiments of the invention, the apparatus may further include a pathway for movement of the reservoir. The initial movement of the plunger may impel the reservoir along the pathway.


According to some embodiments of the invention, the pathway may be substantially parallel to the surface.


According to some embodiments of the invention, the plunger may be configured for discharging a liquid having a viscosity of at least 10 centipoise.


According to some embodiments of the invention, the plunger may be configured for discharging at a substantially constant rate for at least 1 minute.


According to some embodiments of the invention, the reservoir may be configured for long term storage of the drug inside of the apparatus.


According to some embodiments of the invention, the apparatus may further include a hypodermic needle and a needle release for inserting the hypodermic needle into the recipient. The needle release may be synchronized to the plunger.


According to some embodiments of the invention, a direction of the needle release may be non-parallel to a direction of the movement of the plunger.


According to some embodiments of the invention, a direction of the needle release may be substantially orthogonal to a direction of the movement of the plunger.


According to some embodiments of the invention, the apparatus may further include a processor for controlling the controlled rate power source.


According to some embodiments of the invention, the apparatus may further include a septum located in a needle opening of the apparatus. Upon release of a hypodermic needle, the hypodermic needle may puncture the septum before being inserted into the recipient.


According to some embodiments of the invention, the apparatus may further include a rotation sensor. The controlling may be according to an output of the rotation sensor.


According to some embodiments of the invention, the apparatus may further include a rotation sensor. The processor may sense the puncturing of the seal based on an output of the rotation sensor.


According to some embodiments of the invention, the hollow needle may be initially in fluid communication with the reservoir. The seal may be configured for sealing the hollow needle.


According to some embodiments of the invention, the reservoir may include a cartridge insertable into the apparatus.


According to an aspect of some embodiments of the present invention there is provided a method for delivering a drug to a recipient with a delivery apparatus. The drug may be contained in a reservoir initially sealed by a seal for long term aseptic storage. The delivery apparatus may include a hollow needle and a plunger. The method may include attaching a surface of the delivery apparatus to the recipient. The method may also include applying a force with the plunger to a contents of the reservoir. The method may also include puncturing the seal with the hollow needle by the force. The method may also include discharging the drug from the reservoir by the force subsequent to the puncturing. The method may also include detecting a rate of the discharging, and the method may also include adjusting the rate of the discharging based on a result of the detecting.


According to some embodiments of the invention, the applying of the force may be in a direction substantially parallel to the surface.


According to some embodiments of the invention, the method may further include supplying a torque, and converting the torque into the force.


According to some embodiments of the invention, the detecting may be by measuring a rotation driven by the torque.


According to some embodiments of the invention, the discharging may be at a substantially constant rate for at least 1 minute.


According to some embodiments of the invention, the method may further include releasing a hypodermic needle into the recipient by the apparatus subsequent to the puncturing.


According to some embodiments of the invention, the method may further include releasing a hypodermic needle by the apparatus into the recipient in a direction non-parallel to the applying of the force.


According to some embodiments of the invention, the method may further include releasing a hypodermic needle by the apparatus into the recipient in a direction substantially orthogonal to the applying of the force.


According to some embodiments of the invention, the method may further include sensing by the delivery apparatus of a puncturing of the seal.


According to an aspect of some embodiments of the present invention, there is provided a method for delivering a drug to a recipient with a delivery apparatus, the apparatus may include an internal space initially sealed by a septum for long teen aseptic storage. The delivery apparatus may also include a needle and a processor. The method may include attaching a surface of the delivery apparatus to the recipient. The method may also include puncturing the septum with the needle in response to a command of the processor. The method may also include discharging the drug subsequent to puncturing the septum. The method may also include, detecting a rate of the discharging and adjusting by the processor of the rate of the discharging based on a result of the detecting.


According to some embodiments of the invention, the discharging may be driven by an actuator.


According to some embodiments of the invention, the puncturing may be triggered by the actuator.


According to some embodiments of the invention, the actuator may include a motor. The method may further include transforming a rotational motion of the motor into a linear motion. The discharging may be driven by the linear motion.


According to some embodiments of the invention, the septum may seal a needle opening in a housing of the apparatus.


According to some embodiments of the invention, the needle may include a hypodermic needle. The method may further include inserting the hypodermic needle into the recipient subsequent to the puncturing and prior to the discharging.


According to an aspect of some embodiments of the present invention, there is provided an apparatus wearable by a recipient for delivering a drug to the recipient. The apparatus may include an initially aseptic internal space. The apparatus may also include a septum initially sealing the internal space. The apparatus may also include a controlled rate power source. The apparatus may also include a plunger driven by the controlled rate power source, and a hollow needle. The controlled rate power source may trigger puncturing the septum by the hollow needle, and subsequently, the power source may drive movement of the plunger, discharging the drug from the reservoir.


Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains.


Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.


Implementation of the method and/or system of embodiments of the invention can involve performing or completing selected tasks manually, automatically, or a combination thereof. Moreover, according to actual instrumentation and equipment of embodiments of the method and/or system of the invention, several selected tasks could be implemented by hardware, by software or by firmware or by a combination thereof using an operating system.


For example, hardware for performing selected tasks according to embodiments of the invention could be implemented as a chip or a circuit. As software, selected tasks according to embodiments of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In an exemplary embodiment of the invention, one or more tasks according to exemplary embodiments of method and/or system as described herein are performed by a data processor, such as a computing platform for executing a plurality of instructions. Optionally, the data processor includes a volatile memory for storing instructions and/or data and/or a non-volatile storage, for example, a magnetic hard disk and/or removable media, for storing instructions and/or data. Optionally, a network connection is provided as well. A display and/or a user input device such as a keyboard or mouse are optionally provided as well.





BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.


Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.


In the drawings:



FIG. 1 is a flow chart illustrating an exemplary embodiment of a method for unsealing a reservoir and delivering a drug;



FIG. 2A is a perspective external view of an exemplary embodiment of an apparatus for puncturing a septum and delivering a drug;



FIG. 2B is a simplified cutaway view of an exemplary embodiment of an apparatus for puncturing a septum and delivering a drug prior to puncturing the septum;



FIG. 2C is a simplified cutaway view of the embodiment of FIG. 2B after puncturing the septum;



FIG. 2D is a simplified cutaway view of the embodiment of FIG. 2B while delivering the drug;



FIG. 3 is a perspective view of the mechanism of another exemplary embodiment of an apparatus for delivering a drug wherein a septum seals a needle prior to puncturing the septum;



FIG. 3A is a close perspective view of the septum of the embodiment of FIG. 3 prior to puncturing the septum;



FIG. 4 is a perspective view of the mechanism the embodiment of FIG. 3 after puncturing the septum;



FIG. 4A is a close perspective view of the septum of the embodiment of FIG. 3 after puncturing the septum;



FIG. 5 is a cutaway view of a further exemplary embodiment of an apparatus for delivering a drug wherein a septum seals a vial prior to puncturing the septum;



FIG. 6 is a cutaway view of the embodiment of FIG. 5 after puncturing the septum;



FIG. 7A illustrates a perspective view of an exemplary embodiment of a needle insertion mechanism with a septum, prior to releasing the needle;



FIG. 7B illustrates a perspective view of an exemplary embodiment of a needle insertion mechanism with a septum after releasing of the needle;



FIG. 7C illustrates a cutaway perspective view of an exemplary embodiment of an injection apparatus with a septum and a needle release, previous to releasing the needle;



FIG. 7D illustrates a cutaway perspective view of an exemplary embodiment of a injection apparatus with a septum and a needle release, after releasing the needle, and



FIG. 8 is a flowchart illustrating an exemplary embodiment of a method for delivering a drug to a recipient with an initially sealed injector.





DETAILED DESCRIPTION OF THE INVENTION

The present invention, in some embodiments thereof, relates to an apparatus wearable by a recipient and method for delivering a substance to a recipient, more particularly, but not exclusively, to an apparatus with a single-motion controlled-rate power train for sequentially unsealing a reservoir containing a drug and delivering the drug to a recipient.


In some embodiments, an unsealing mechanism may use the existing drive train of the drug discharge device to unseal a drug reservoir. For example, the drive train may include a plunger. Optionally, while the reservoir is sealed, the plunger may drive the syringe along a pathway to an unsealing mechanism. Optionally after unsealing the reservoir, further motion of the plunger may drive discharging of the drug.


In some embodiments, the apparatus may be worn by the recipient. Wearing the apparatus may include, for example, attaching a base of the apparatus to the recipient and/or carrying the apparatus attached to clothing of the recipient and/or strapping the apparatus to the recipient. For example, the base of the apparatus may stick to the skin of the recipient (for example via an adhesive).


In some embodiments, the pathway of movement of the syringe may be parallel to the base of the apparatus.


Controlled Rate Deliver


In some embodiments, the rate of delivery may be controlled. Optionally a drug may be delivered as a bolus injection and/or continuously and/or at a slow rate and/or at a fast rate. Optionally the rate of delivery may be adjustable. In some embodiments, the maximum rate of delivery may optionally be between 10 ml/hr and 100 ml/hr. Optionally, the total delivered volume may be between 0.5 ml and 20 ml. In some embodiments, the total time of delivery may be between 5 seconds and 20 minutes. Optionally, the total time of delivery may be measured from the beginning of delivery until the end of delivery. Optionally, the beginning of deliver may be measured from the time of activation of the apparatus and/or alternatively from the time of attachment of the apparatus and/or alternatively from the time that delivery of the substance begins. Optionally the end of delivery may be measured at deactivation of the apparatus and/or alternatively at the earliest time after which no more of the substance is delivered and/or alternatively when the apparatus is removed from the recipient. Optionally the drug may be delivered in a single dose and/or at a constant rate.


In some embodiments, a drug pump may be a programmable device. For example, the pump may be capable of controlled delivery of a substance according a preprogrammed schedule and/or rate. Alternatively or additionally, the pump may be a smart device capable of changing a delivery schedule according to commands and/or in reaction to changing conditions. Optionally, the device may be capable of stopping and restarting delivery.


Sealed for Long Term Storage and Ready to Use


A drug may require strictly prescribed packaging. Legal, health and safety requirements may include very stringent packaging standards. Packages may need to be aseptic, packaging materials may be strictly limited and package geometry may be very precisely stipulated. For example, when a drug is to be stored for a significant period of time (for example more than 24 hours and/or more than a month) standards may be particularly stringent.


In some cases, it may be inconvenient for the recipient to prepare a drug for delivery and/or to produce a coordinated force to activate a mechanical trigger. For example, the recipient may include a child and/or the medical procedures may induce fatigue or confusion in the recipient (for example chemotherapy). In some cases, the recipient may have a condition that makes it difficult to perform precise tasks (for example rheumatism and/or Parkinson's disease, and/or partial paralysis of the fingers). More generally, opening packaging and then loading the delivery device may be inconvenient and may increase the probability of exposure to contamination or of error or loss of the drug.


It is sometimes desirable to supply a recipient with a delivery device that can be stored. It may also be desirable to supply the delivery device ready to use to deliver a medicine. For example, at a certain time following an outpatient hospital procedure, it may be desirable to deliver a drug to the patient (for example an antidote to chemotherapy agent). Sometimes before a hospital procedure, it may be desirable to deliver a drug to a patient (for example a dye before a radiological diagnostic procedure). A recipient may prefer to receive these drugs from a portable drug pump rather than traveling to a clinic.


In some embodiments, the apparatus may be supplied with a sealed reservoir having an internal space containing a drug. The apparatus may deliver the drug automatically with minimum involvement of the recipient. Optionally, the delivery apparatus may function independently requiring minimal or no cooperation and/or awareness and/or activity of the recipient. For example, a doctor may attach the device to the recipient and the device may take care of delivery of the drug at the proper time without involvement of the recipient. Alternatively or additionally, a recipient may be given a single packaged device and the recipient may be able to take the drug at the required by merely attaching and activating the device.


In some embodiments, a drug reservoir may be sealed by a septum. Optionally, unsealing the reservoir may be by puncturing the septum.


In some embodiments, a drug may be packaged in a vial sealed by a septum. Optionally, the septum may be punctured by inserting a hollow needle through the septum into the vial.


In some embodiments, the drug may be packaged in a syringe. Optionally, a needle of the syringe may be sealed by an insertion into a septum. Optionally, unsealing may be achieved by pushing the needle of the syringe through the septum.


In some embodiments, unsealing a package includes piercing a septum. The septum may include, for example, many kinds of seals including caps, stoppers, plugs, diaphragms and/or partitions of various thicknesses. For example, a septum or a seal may be made from plastic, rubber, silicone, a gel, a metal foil, a polymer and/or a combination thereof.


Portable and/or Low Profile


Optionally, the apparatus may not require conscious carrying by the recipient. Optionally, the apparatus may minimally disturb the recipient. For example, a pump may be small and/or have a low profile. For example, some embodiments of a drug pump may be worn inconspicuously under a recipient's clothing. The height of the apparatus may be less than the square root of the area of the base.


Optionally, the base of the apparatus may be less than 5 cm long and/or less than 5 cm wide. Optionally, the height of the apparatus may be less than 3 cm. Optionally, the total volume of the apparatus may be less than 100-200 ml. Optionally, the mass of the entire apparatus with the substance may be less than 100-200 g. Optionally, the capacity of the reservoir for the substance in the apparatus may be between 5-30 ml). Optionally, the apparatus may be shock proof and/or waterproof.


The term “reservoir” throughout the specification and claims encompasses any container for a drug, such as but not limited to, a cartridge, vial, syringe, bottle, ampoule and many more, and is not limited to any size or shape. Optionally, the reservoir may be packed and/or stored in the injector. Alternatively or additionally, the reservoir may include a cartridge that is stored separately from the delivery device and inserted into the delivery device at a convenient time.


In some embodiments, the apparatus may be easily disposable (for example in municipal garbage).


Caveats


In some embodiments, the apparatus is a medicine pump. The invention is not limited to a drug pump, and may be used for any kind of suitable discharge apparatus, not just by needle piercing the patient, but also transdermally (wherein the substance is metered by the apparatus to a transdermal patch), by spray (wherein the substance is metered by apparatus to a spray nozzle), micro needles array and others.


Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details of construction and the arrangement of the components and/or methods set forth in the following description and/or illustrated in the drawings and/or the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.


Flow Chart of a Method of Delivery of a Drug



FIG. 1A is a flow chart illustrating an exemplary method of delivering a drug. In the example, a patient prefers to take a drug injection at home and not remain in a medical institution waiting for a nurse to administer the injection. In the exemplary embodiment, the institution is supplied with a portable preloaded automatic apparatus that can be stored until the recipient needs the drug. When the drug is needed, the apparatus is optionally attached to the recipient and/or activated. Optionally, the apparatus takes care of preliminary activities (for example unsealing the drug reservoir and/or inserting a needle into the recipient). The pump then makes the injection and optionally takes care of preparing itself for disposal.


In the exemplary embodiment of FIG. 1, the apparatus is optionally supplied 100 to a medical institution preloaded with the drug and preprogrammed. For example, the substance to be injected may be an antidote to a chemotherapy agent to be injected twelve hours after the therapy. Optionally, the antidote is packaged inside the apparatus in a sealed vial. Optionally, the preloaded apparatus may be stored 102 in a medical institution for a time ranging from a few days to a few months before actually being used. Alternatively or additionally, the apparatus may be supplied to the recipient by, for example, a pharmacy and stored by the recipient for a time ranging from a day to a few months until needed. Alternatively or additionally, the sealed vial may be stored separately from the apparatus. Optionally, vial may be loaded into the apparatus by the distributor and/or by a pharmacist and/or by a medical professional (for example a nurse or a doctor) and/or by the recipient himself.


In the example of FIG. 1, the apparatus is programmed to deliver the entire contents of the reservoir 12 hours after activation in a constant rate injection. Alternatively or additionally, the apparatus may be programmed to deliver a portion of the medicine in a single dose. Optionally the apparatus may be programmed to administer a second dose. Optionally the second dose may be delivered after a fixed time delay and/or the second dose may be delivered on demand of the recipient and/or upon a combination of time delay and command and/or in reaction to some other stimulus.


In the example of FIG. 1, when the apparatus is needed, the apparatus is optionally attached 104 to a recipient. Attachment may be, for example by an adhesive pad on a base surface of the housing of the apparatus. After attachment, the apparatus is activated 106. Alternatively or additionally, the apparatus may be activated first and then attached to the recipient.


Once activated 106, in some embodiments, the apparatus may perform preliminary steps before discharging the drug. Optionally, the preliminary steps may be preprogrammed into the apparatus logic. For example, at a preprogrammed injection time, the apparatus may insert 108 a needle into the recipient. After insertion 108, a reservoir containing the drug may optionally be unsealed 110. For example, the reservoir may include a vial sealed by a septum and the unsealing 110 may be by puncturing the septum. Alternatively or additionally, inserting the needle into the recipient may follow unsealing the reservoir.


In some embodiments, inserting 108 a needle into the recipient and unsealing 110 the reservoir may open a fluid path between the reservoir and the recipient. Once the fluid path is open, the drug is discharged 112 into the recipient at a dosage and rate that is optionally controlled by a controller of the injection apparatus.


In some embodiments, discharge 112 of the drug will start quickly after unsealing 110 the reservoir and/or inserting 108 the needle. For example, in some embodiments discharging 112 will start less than 5 minutes after inserting 108 and/or unsealing 110. In some embodiments, discharging 112 will start less than one minute after inserting 108 and/or unsealing 110. In some embodiments, there may be a short delay after unsealing 110 the reservoir and/or inserting 108 the needle before discharging 112 the substance. In some embodiments, the delay may range between 30 seconds and 5 minutes.


In some embodiments, the apparatus may perform post injection tasks. For example, after the drug has been fully or partially discharged 112, an optional chaser of for example saline solution may be injected. The apparatus may optionally be automatically permanently deactivated 114. For example, deactivation may include retracting the needle. Once the apparatus is deactivated, it may be removed 116 from the recipient and discarded 118. Additionally or alternatively, the apparatus may be removed from the recipient and then disabled. For example, upon removal of an injection apparatus, the needle may be retracted and/or a cover may be deployed to protect the needle.


Optionally, some or all of insertion 108 of the needle and/or unsealing 110 of the reservoir and/or discharging 112 and/or deactivation 114 of the apparatus may be triggered and/or driven by a single motion of an actuator. For example, the actuator may include an electric motor and/or a screw and/or a piston. The motion may optionally be continuous. Alternatively or additionally, the injector may be programmed by the distributor and/or medical personnel (for example a nurse, a doctor or a pharmacist) and/or by the recipient.


An External View of a Low Profile Drug Injector



FIG. 2A illustrates an external view of an exemplary embodiment 210 of a drug delivery apparatus (a subcutaneous injector apparatus). During use of embodiment 210, a base surface 220 is stuck to the recipient's skin with an adhesive. A needle 222 extends out a needle opening 229 into a recipient. The drug is discharged via needle 222 into the recipient. Optionally, embodiment 210 is has a large base 220 (for example, the length and width of base 220 is 4 cm by 6 cm) and a low profile (for example, the height 224 of the apparatus is 2 cm). In exemplary embodiment 210, height 224 of the apparatus is less than half the square root of the surface area of base 220. In some embodiments, the height may be less the 1.4 times the square root of the surface area of the base. Embodiment 210 may be stabile when stuck to the recipient's skin. Embodiment 210 may be inconspicuous when worn under clothing.


A locking door 226 may optionally be provided. Door 226 may prevent tampering with the drugs inside the injector. It is noted that although embodiment 210 is typically a one-use item, the electronics, batteries and motor and other elements of the system can be used more than once if desired.


A Schematic Cutaway Illustration of a Drug Pump Puncturing a Septum



FIGS. 2B-D are schematic cutaway side views illustrating exemplary embodiment 210 of a drug delivery apparatus puncturing a septum and delivering a drug.



FIG. 2B illustrates exemplary embodiment 210 in an initial state. In the example, base 220 of the apparatus is attached to the flesh 211 of a recipient. Hypodermic needle 222 protrudes from base 220 of the apparatus into the flesh 211 of the recipient. Optionally, hypodermic needle 222 may be inserted into the recipient by a release mechanism. In some embodiments, needle 222 protrudes perpendicular to base 220.


In the example, a reservoir 234 is in fluid contact with a hollow needle 232. Optionally, reservoir 234 and consequently needle 232 are held in place, using low friction pads 246 and 246′. In the example, in the initial state, reservoir 234 is placed towards the rear (left side) of the apparatus so that there is a gap 244 between a flange 248 of reservoir 234 and pad 246. In the initial state, needle 232 and consequently reservoir 234 are sealed by a septum 236.


Some embodiments may include a plunger assembly 256 that translates circular motion of a gear 242 into linear motion. In the exemplary embodiment, activating a motor supplies a torque to turn gear 242 and screw 243. Optionally, the housing of the apparatus prevents translation motion of gear 242 and screw 243.


In some embodiments, rotation of screw 243 causes plunger assembly 256 to telescope. While reservoir 234 is sealed, telescoping of assembly 256 pushes reservoir 234 along a path parallel to base 220 of the apparatus. This advances needle 232 through septum 236. Eventually, needle 232 pierces septum 236, unsealing reservoir 234 as shown, for example, in FIG. 2C.


In embodiment 210, the pathway of movement of reservoir 234 is parallel to the base of the apparatus. In embodiment 210, the pathway of movement of a plunger 258 is parallel to the base of the apparatus. In embodiment 210, the long axis of reservoir 234 is parallel to the base of the apparatus. The Length of base 220 of exemplary embodiment 210 is longer than the height 224 of the apparatus. In some embodiments, the long axis of and/or the pathway followed by reservoir 234 may be directed non-parallel to and/or orthogonal to hypodermic needle 222.


In FIG. 2C, the exemplary embodiment is shown with needle 232 puncturing septum 236. In the example, flange 248 is in contact with pad 246 stopping further forward movement of reservoir 234.


In some embodiments, puncturing septum 236 creates a fluid pathway from reservoir 234 through hollow needle 232 and through a canal 250 and through hypodermic needle 222 to flesh 211 of the recipient.


In the exemplary configuration of FIG. 2C, further, telescoping of assembly 256 advances a plunger 258 inside of reservoir 234 as illustrated, for example, in FIG. 2D. Advancement of plunger 258 discharges the drug out of needle 232, canal 250 and needle 222 into flesh 211 of the recipient.


A Syringe Reservoir with a Needle for Puncturing a Septum



FIGS. 3, 3A, 4 and 4A illustrate another exemplary embodiment 310 of a drug delivery apparatus. In embodiment 310, a syringe needle 332 is mounted to a reservoir 334. In FIGS. 3 and 3A needle 332 is shown sealed by an optional septum 336. In FIGS. 4 and 4A needle 332 is shown puncturing septum 336 to unseal reservoir 334.



FIGS. 3 and 4 illustrate an optional programmable controller 328 capable of directing an optional power actuator 330 for powering discharging of a substance. In addition, FIGS. 3, 3A, 4 and 4A illustrate how actuator 330 may optionally drive puncturing of septum 336 and/or trigger insertion of a needle into the recipient.


In some embodiments, controller 328 may be a programmable electronic processor. Controller 328 may optionally include a memory.


In some embodiments, actuator 330 may include a direct current (DC) electric motor. Power for controller 328 and actuator 330 may be supplied by a power supply 338 (for example batteries). Controller 328 may optionally direct actuator 330 by pulse width modulation (PWM). Alternatively or additionally, actuator 330 may include a brushless DC servo (for example a stepper motor) directed by controller 328. In some embodiments, the rate of rotation of actuator 330 may be adjustable. The rate of discharge of the drug may correspond to the rate of rotation of the actuator 330. Optionally, rate of rotation of the actuator 330 may be adjusted by programming controller 328 and/or by a user interface (for example a dial and/or button) on the apparatus.


Embodiment 310 includes an optimal rotation sensor 340. In some embodiments rotation sensor 340 may include an optical sensor that detects movements of a paddle. Alternatively or additionally, rotation sensor may include a Hall Effect sensor or the like. Optionally, if actuator 330 fails to rotate and/or rotates too slowly upon application of power, controller 328 may notify the recipient of a malfunction. Other malfunctions that may be detected include not enough voltage, not enough current, too much current, and/or too fast rotation.


In FIGS. 3 and 3A, a drug reservoir 334 is shown in a sealed configuration. Reservoir 334 is held in place for example by low friction pads 346 and 346′. In the sealed configuration, needle 332 is optionally sealed by septum 336, for example, as illustrated in FIG. 3A.


In some embodiments, when reservoir 334 is in the sealed configuration, a gap 344 exists between a flange 348 of reservoir 334 and friction pad 346.


In some embodiments, a transmission including gears 342 and a drive train (not show) connect actuator 330 to a telescoping plunger assembly (for example see plunger assembly 456FIG. 4) located inside reservoir 334. A more detailed view of an exemplary embodiment of a plunger assembly 556 is shown in FIGS. 5 and 6. Alternatively or additionally, a plunger assembly may include a linear actuator. In exemplary embodiment 310, the transmission includes a gear, but alternatively or additionally, it could include another coupling element for transmitting rotary motion, such as a friction wheel. Optionally rotation of actuator 330 drives expansion of telescoping plunger assembly 456. Alternatively or additionally, the drive mechanism may include an expanding gas chamber. For example, expanding gas may be produced by an electrolytic cell and/or by a chemical reaction. Alternatively or additionally, the reservoir may have flexible walls. Optionally, discharge may include deforming and/or squeezing the reservoir.


In embodiment 310, while reservoir 334 is in the sealed configuration of FIGS. 3 and 3A, expansion of plunger assembly 456 drives reservoir 334 and needle 332 forward. Optionally, forward motion stops when flange 348 contacts friction pad 346, which acts as a stop along the pathway of movement of reservoir 334.


In some embodiments, forward movement of reservoir 334 pushes needle 332 through septum 336 putting the apparatus into the discharge configuration, for example, as illustrated in FIG. 4. In the discharge configuration, a gap 444 has formed behind flange 348. The rear end of telescoping plunger assembly 456 can be seen in gap 444. In the discharge configuration, needle 332 has fully punctured septum 336, unsealing reservoir 334. A fluid path exists from reservoir 334 through needle 332 to a canal 350.


In embodiment 310, the pathway of movement of reservoir 334 is parallel to the base of the apparatus. In embodiment 310, the pathway of movement of plunger assembly 456 is parallel to the base of the apparatus. In embodiment 310, the long axis of reservoir 334 is parallel to the base of the apparatus. The base of the apparatus is longer than the height of the apparatus.


Embodiment 310 includes an optional trigger arm 352 for triggering a needle release 354. As reservoir 334 moves forward it displaces arm 352 causing needle release 354 to insert a hypodermic needle (not shown) into the recipient. A tube (not shown) supplies a fluid pathway from canal 350 to the hypodermic needle. In the discharge configuration, there is a fluid pathway from reservoir 334 to the recipient. Optionally, the hypodermic needle may be inserted into the recipient either before or after completing puncturing of septum 336. Alternatively or additionally, controller 328 may directly control needle release 354. Optionally, the direction of release of the needle may be non-parallel and/or orthogonal to the direction of movement of plunger assembly 456.


In the example of embodiment 310, telescoping plunger assembly 456 includes a threaded member to convert rotational motion of actuator 330 into expansion and translational motion of the plunger assembly 456. Optionally, in embodiment 310 rotation of sensor 340 may be directly proportional translational movement. In embodiment 310, measurements of rotation can be used to sense the position of the translational mechanism. By means of measurements of the rotation of actuator 330, controller 328 optionally tracks the location of telescoping plunger assembly 456 and/or of reservoir 334 and/or of needle 332. Optionally the rate of discharge of the drug may be detected by measuring a rate of rotation of sensor 340. Optionally, the state of the septum 336 (for example whether plunger assembly 456 has advanced far enough to puncture septum 336) and/or the cumulative volume of medicine discharged may be sensed based on the cumulative number of revolutions of rotation sensor 340.


In embodiments 310, when reservoir 334 is in the discharge configuration, friction pad 346 prevents further forward motion of reservoir 334. As stated above, in the discharge configuration, there is a fluid flow path from reservoir 334 into the recipient. Further expansion of the plunger assembly 456 forces the plunger assembly 456 into reservoir 334 discharging the contents of reservoir 334 out needle 332 into canal 350 and out canal 350 through the hypodermic needle into the recipient.


A Reservoir where a Hollow Needle is Inserted into a Vial Through a Septum



FIG. 5 is a cutaway illustration of an exemplary embodiment 510 of a drug delivery apparatus. In embodiment 510, a reservoir is sealed by a septum. Optionally, the septum is punctured by driving the reservoir toward a hollow needle until a needle point 560 of the needle punctures the septum. Upon puncturing the septum, the point 560 of the needle enters the reservoir. Subsequently, the hollow of the needle provides for fluid communication between the reservoir and the external environment.


Embodiment 510 includes a reservoir 534 sealed by a cartridge seal or septum 536. Optionally, reservoir 534 may be placed a bit away from a hollow needle 532 in a sealed configuration (For example, as illustrated in FIG. 5). Reservoir 534 may be held in place, for example, using low friction pads 546, with needle 532 against and/or partially inserted into and/or adjacent to septum 536.


In embodiment 510, activating a motor 530 may cause a telescoping assembly 556 to telescope, pushing a plunger 558 into reservoir 534. In the example of embodiment 510, telescoping plunger assembly 556 includes concentrically mounted threaded members to convert rotational motion of an actuator, motor 530, into expansion of telescoping assembly 556 and translation of plunger 558. Because reservoir 534 is sealed, translation of plunger 558 advances reservoir 534 against needle 532, puncturing septum 536 (as shown, for example, if FIG. 6). Optionally, reservoir 534 translates forward until a cap 548 of reservoir 534 crosses a gap 544 and contacts a stop 549.


Puncturing septum 536 creates a fluid flow path between reservoir 534 and the recipient's body. The flow path allows further translation of plunger 558 to produce fluid flow out needle 532 and through a tube (not shown) into a hypodermic needle (not shown) and into the recipient.


Embodiment 510 includes further optional components, for example batteries 538, and a needle release 554, and a rotation sensor 540, and a controller 528, and a transmission 542.


A Septum Preserving Aseptic Conditions of a Hypodermic Needle



FIGS. 7A and 7B illustrate perspective views of an exemplary embodiment of a needle insertion mechanism 754 with a needle opening septum 764. Needle opening septum 764, seals a needle opening, preserving aseptic conditions inside an injector (as illustrated, for example, in FIG. 7C).


In some embodiments, when the apparatus is attached to a recipient, when needle 722 is released, it may optionally pass through needle opening septum 764 (as illustrated, for example, in FIG. 7B) and be inserted into the flesh of the recipient.


In some embodiments, prior to release, needle 722 may be partially inserted into needle opening septum 764 (for example as illustrated in FIG. 7A). While partially inserted, the distal opening 723 at the needle tip 721 of needle 722 may be sealed by needle opening septum 764. Needle 722 may be in fluid communication with a drug reservoir. Sealing needle 722 may seal the reservoir. Alternatively or additionally, prior to release, a hypodermic needle 722′ may be held clear of a needle opening septum 764′, as illustrated, for example in FIG. 7C).


In the example of FIGS. 7A and 7B, a motor 730 rotates a shaft 760. Rotation of shaft 760 optionally causes a threaded arrester 762 to slide out of an opening in insertion mechanism 754 releasing needle 722. A biasing member 725 biases the needle 722 toward the released position (FIG. 7B) such that when the threaded arrester 762 disengages from the insertion mechanism, the needle is transferred to the released position. In some embodiments, motor 730 may also trigger unsealing a reservoir and discharging of a drug (as illustrated, for example, above). An optional rotation sensor includes sensors 741, which sense revolutions of a paddle 740.


In some embodiments, needle opening septum 764′ may be fixed to the housing 765 of the injection apparatus. For example, FIGS. 7C and 7D are cutaway perspective illustrations of an exemplary embodiment where needle opening septum 764′ is connected to a base 720 of the housing 765 of the injection apparatus. FIG. 7C illustrates the exemplary embodiment prior to release of a needle 722′ by a release 754′. In the illustration, needle opening 729′ is sealed by needle opening septum 764′. FIG. 7D illustrates the exemplary embodiment after release of needle 722′ and after needle 722′ punctures needle opening septum 764′.



FIG. 8 is a flow chart illustration of an exemplary embodiment of a method for delivering a drug to a recipient. In some embodiments, an injector apparatus may be supplied 870 in a sealed state. Optionally in the sealed state, an internal space of the injector may be preserved 872 in an aseptic state by a septum. Optionally, a hypodermic needle may be stored in the aseptic internal space of the injector.


In some embodiments, the apparatus may be attached 874 to the recipient while still in the sealed state. For example, a base of the apparatus may be stuck to the recipient using an adhesive.


In some embodiments, there may be a release mechanism. The mechanism may release 876 the needle. For example, the needle may be released 876 after attachment 874 of the apparatus to the recipient. Optionally upon release 876, the needle may puncture 878 the septum.


In some embodiments, the needle may continue through the septum, through a needle opening in the base of the apparatus and be inserted 880 into the recipient.


Once the needle is inside the recipient, a drug may optionally be delivered 882 through the needle into the recipient.


Caveats


It is expected that during the life of a patent maturing from this application many relevant technologies will be developed and the scope of the terms is intended to include all such new technologies a priori.


As used herein the term “about” refers to ±10%.


The terms “comprises”, “comprising”, “includes”, “including”, “having” and their conjugates mean “including but not limited to”.


The term “consisting of means “including and limited to”.


The term “consisting essentially of” means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.


As used herein, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a compound” or “at least one compound” may include a plurality of compounds, including mixtures thereof.


Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.


Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases “ranging/ranges between” a first indicate number and a second indicate number and “ranging/ranges from” a first indicate number “to” a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.


It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.


It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.

Claims
  • 1. A wearable drug delivery apparatus for administering a drug to a recipient, the drug delivery apparatus comprising: a housing having a base surface configured to be positioned proximate the subject's skin, the base surface having a needle opening therein;a controlled rate power actuator;a cartridge positioned within the housing, having a longitudinal axis being substantially parallel to the base surface, the cartridge containing the drug therein and having one of a septum or a piercing needle and the housing having the other of the septum and the piercing needle, the cartridge being movable by the power actuator from a sealed position, wherein the piercing needle is sealed by the septum, to a discharge position, wherein the piercing needle punctures through the septum;a plunger movably mounted in the cartridge, the plunger being movable by the power actuator along the longitudinal axis;an injection needle fluidly connectable to the cartridge and having a needle tip including an opening, the needle tip being movable by a biasing member from a retracted position, wherein the needle tip is located within the housing, to a released position, wherein the needle tip extends through the needle opening and is located outside of the housing;a trigger arm triggering the release of the needle tip into the released position when the trigger arm is moved by the cartridge as the cartridge is moved from the sealed position to the discharge position; andan injection needle septum positioned in the housing;wherein the needle tip is inserted in the injection needle septum, sealing the needle tip opening in the retracted position, and the needle tip penetrates through the injection needle septum in the released position.
  • 2. The drug delivery apparatus of claim 1, wherein the injection needle septum is positioned within the needle opening.
  • 3. The drug delivery apparatus of claim 1, wherein the needle tip is oriented substantially perpendicular to the base surface.
  • 4. The drug delivery apparatus of claim 1, wherein the needle tip is injected into the subject's skin in the released position.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 14/510,846, filed Oct. 9, 2014, entitled “Motion Activated Septum Puncturing Drug Delivery Device,” which is a continuation of similarly-titled U.S. application Ser. No. 13/429,942, filed Mar. 26, 2012, now U.S. Pat. No. 9,463,280, the disclosure of each of which is incorporated herein by reference in its entirety.

US Referenced Citations (428)
Number Name Date Kind
3946732 Hurscham Mar 1976 A
3994295 Wulff Nov 1976 A
4167663 Granzow, Jr. et al. Sep 1979 A
4273122 Whitney et al. Jun 1981 A
4396385 Kelly et al. Aug 1983 A
4601702 Hudson Jul 1986 A
4634426 Kamen Jan 1987 A
4886499 Cirelli et al. Dec 1989 A
4919596 Slate et al. Apr 1990 A
4950235 Slate et al. Aug 1990 A
4950246 Muller Aug 1990 A
5109850 Blanco et al. May 1992 A
5131816 Brown et al. Jul 1992 A
5254096 Rondelet et al. Oct 1993 A
5342313 Campbell et al. Aug 1994 A
5354287 Wacks Oct 1994 A
5383865 Michel Jan 1995 A
5411482 Campbell May 1995 A
5501665 Jhuboo et al. Mar 1996 A
5558639 Gangemi Sep 1996 A
5593390 Castellano et al. Jan 1997 A
5616132 Newman Apr 1997 A
5643218 Lynn et al. Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5658133 Anderson et al. Aug 1997 A
5690618 Smith et al. Nov 1997 A
D393314 Meisner et al. Apr 1998 S
5800420 Gross et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5814020 Gross Sep 1998 A
5851197 Marano et al. Dec 1998 A
5858001 Tsals et al. Jan 1999 A
5858008 Capaccio Jan 1999 A
5931814 Alex et al. Aug 1999 A
5957895 Sage et al. Sep 1999 A
5993423 Choi Nov 1999 A
5997501 Gross et al. Dec 1999 A
6004297 Steenfeldt-Jensen et al. Dec 1999 A
6064797 Crittendon et al. May 2000 A
6074369 Sage et al. Jun 2000 A
6175688 Cassidy et al. Jan 2001 B1
6186982 Gross et al. Feb 2001 B1
6200289 Hochman et al. Mar 2001 B1
6248093 Moberg Jun 2001 B1
6277095 Kriesel et al. Aug 2001 B1
6277098 Klitmose et al. Aug 2001 B1
6277099 Strowe et al. Aug 2001 B1
6287283 Ljunggreen et al. Sep 2001 B1
6362591 Moberg Mar 2002 B1
6391005 Lum et al. May 2002 B1
6423029 Elsberry Jul 2002 B1
6423035 Das et al. Jul 2002 B1
D465026 May et al. Oct 2002 S
6458102 Mann et al. Oct 2002 B1
6485461 Mason et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6500150 Gross et al. Dec 2002 B1
6517517 Farrugia et al. Feb 2003 B1
D471274 Diaz et al. Mar 2003 S
D471983 Hippolyte et al. Mar 2003 S
6530901 Tsukada et al. Mar 2003 B1
6555986 Moberg Apr 2003 B2
6558351 Steil et al. May 2003 B1
6589229 Connelly et al. Jul 2003 B1
6595956 Gross et al. Jul 2003 B1
6595960 West et al. Jul 2003 B2
6645181 Lavi et al. Nov 2003 B1
6652482 Hochman Nov 2003 B2
6656158 Mahoney et al. Dec 2003 B2
6656159 Flaherty Dec 2003 B2
6659980 Moberg et al. Dec 2003 B2
6673033 Sciulli et al. Jan 2004 B1
6679862 Diaz et al. Jan 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6749587 Flaherty Jun 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6786890 Preuthun et al. Sep 2004 B2
6800071 McConnell et al. Oct 2004 B1
6805687 Dextradeur et al. Oct 2004 B2
6824529 Gross et al. Nov 2004 B2
6843782 Gross et al. Jan 2005 B2
6854620 Ramey Feb 2005 B2
6905298 Haring Jun 2005 B1
6908452 Diaz et al. Jun 2005 B2
6933693 Schuchmann Aug 2005 B2
6950028 Zweig Sep 2005 B2
6960192 Flaherty et al. Nov 2005 B1
7001360 Veasey et al. Feb 2006 B2
7048715 Diaz et al. May 2006 B2
7060059 Keith et al. Jun 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
7193521 Moberg et al. Mar 2007 B2
D544092 Lewis Jun 2007 S
7247149 Beyerlein Jul 2007 B2
7250037 Shermer et al. Jul 2007 B2
7267669 Staunton et al. Sep 2007 B2
7303549 Flaherty et al. Dec 2007 B2
7390314 Stutz, Jr. et al. Jun 2008 B2
7407493 Cane' Aug 2008 B2
7455663 Bikovsky Nov 2008 B2
7459571 Schlitter et al. Dec 2008 B2
7465290 Reilly Dec 2008 B2
7497842 Diaz et al. Mar 2009 B2
7524304 Genosar Apr 2009 B2
7530964 Lavi et al. May 2009 B2
7547281 Hayes et al. Jun 2009 B2
7563253 Tanner Jul 2009 B2
7565208 Harris et al. Jul 2009 B2
7569050 Moberg et al. Aug 2009 B2
D600341 Loerwald Sep 2009 S
7585287 Bresina et al. Sep 2009 B2
7588559 Aravena et al. Sep 2009 B2
D602155 Foley et al. Oct 2009 S
D602586 Foley et al. Oct 2009 S
D604835 Conley Nov 2009 S
7621893 Moberg et al. Nov 2009 B2
7628770 Ethelfeld Dec 2009 B2
7628772 McConnell et al. Dec 2009 B2
7628782 Adair et al. Dec 2009 B2
7637891 Wall Dec 2009 B2
7641649 Moberg et al. Jan 2010 B2
7660627 McNichols et al. Feb 2010 B2
7678079 Shermer et al. Mar 2010 B2
7682338 Griffin Mar 2010 B2
7686787 Moberg et al. Mar 2010 B2
7699829 Harris et al. Apr 2010 B2
7699833 Moberg et al. Apr 2010 B2
7704227 Moberg et al. Apr 2010 B2
7704231 Pongpairochana et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7713238 Mernoe May 2010 B2
7713240 Istoc et al. May 2010 B2
7717913 Novak et al. May 2010 B2
7722574 Toman et al. May 2010 B2
7736344 Moberg et al. Jun 2010 B2
7744589 Mounce et al. Jun 2010 B2
7749194 Edwards et al. Jul 2010 B2
7753879 Mernoe Jul 2010 B2
7766873 Moberg et al. Aug 2010 B2
7776030 Estes et al. Aug 2010 B2
7780636 Radmer et al. Aug 2010 B2
7780637 Jerde et al. Aug 2010 B2
7789857 Moberg et al. Sep 2010 B2
7789862 Thorne, Jr. Sep 2010 B2
7801599 Young et al. Sep 2010 B2
7806868 De Polo et al. Oct 2010 B2
7815622 Istoc et al. Oct 2010 B2
7828528 Estes et al. Nov 2010 B2
7837659 Bush, Jr. et al. Nov 2010 B2
7846132 Gravesen et al. Dec 2010 B2
7857131 Vedrine Dec 2010 B2
7879025 Jacobson et al. Feb 2011 B2
7879026 Estes et al. Feb 2011 B2
7892206 Moberg et al. Feb 2011 B2
7918825 O'Connor et al. Apr 2011 B2
7918843 Genosar et al. Apr 2011 B2
7935104 Yodfat et al. May 2011 B2
7935105 Miller et al. May 2011 B2
7938803 Mernoe et al. May 2011 B2
7955305 Moberg et al. Jun 2011 B2
7967784 Pongpairochana et al. Jun 2011 B2
7981105 Adair et al. Jul 2011 B2
7988683 Adair et al. Aug 2011 B2
7993300 Nyholm et al. Aug 2011 B2
7998111 Moberg et al. Aug 2011 B2
8021357 Tanaka et al. Sep 2011 B2
8025658 Chong et al. Sep 2011 B2
8029469 Ethelfeld Oct 2011 B2
8034019 Nair et al. Oct 2011 B2
8038666 Triplett et al. Oct 2011 B2
8057436 Causey et al. Nov 2011 B2
8062253 Nielsen et al. Nov 2011 B2
8062257 Moberg et al. Nov 2011 B2
8065096 Moberg et al. Nov 2011 B2
8066694 Wagener Nov 2011 B2
D650079 Presta et al. Dec 2011 S
D652503 Cameron et al. Jan 2012 S
8105279 Mernoe et al. Jan 2012 B2
8114046 Covino et al. Feb 2012 B2
8114064 Alferness et al. Feb 2012 B2
8114066 Naef et al. Feb 2012 B2
8147446 Yodfat et al. Apr 2012 B2
8152764 Istoc et al. Apr 2012 B2
8152770 Reid Apr 2012 B2
8152779 Cabiri Apr 2012 B2
8152793 Keinanen et al. Apr 2012 B2
8157693 Waksmundzki Apr 2012 B2
8157769 Cabiri Apr 2012 B2
8162923 Adams et al. Apr 2012 B2
8167841 Teisen-Simony et al. May 2012 B2
8172804 Bikovsky May 2012 B2
8182447 Moberg et al. May 2012 B2
8182462 Istoc et al. May 2012 B2
8197444 Bazargan et al. Jun 2012 B1
8206351 Sugimoto et al. Jun 2012 B2
8267893 Moberg et al. Sep 2012 B2
8267921 Yodfat et al. Sep 2012 B2
8287520 Drew et al. Oct 2012 B2
8308679 Hanson et al. Nov 2012 B2
8348898 Cabiri Jan 2013 B2
8372039 Mernoe et al. Feb 2013 B2
8373421 Lindegger et al. Feb 2013 B2
8409142 Causey et al. Apr 2013 B2
8414557 Istoc et al. Apr 2013 B2
8430847 Mernoe et al. Apr 2013 B2
8469942 Kow et al. Jun 2013 B2
8474332 Bente, IV et al. Jul 2013 B2
8475408 Mernoe et al. Jul 2013 B2
8479595 Vazquez et al. Jul 2013 B2
8483980 Moberg et al. Jul 2013 B2
8495918 Bazargan et al. Jul 2013 B2
8512287 Cindrich et al. Aug 2013 B2
8517987 Istoc et al. Aug 2013 B2
8523803 Favreau Sep 2013 B1
8556856 Bazargan et al. Oct 2013 B2
8574216 Istoc et al. Nov 2013 B2
8603026 Favreau Dec 2013 B2
8603027 Favreau Dec 2013 B2
8617110 Moberg et al. Dec 2013 B2
8628510 Bazargan et al. Jan 2014 B2
8647074 Moberg et al. Feb 2014 B2
8647296 Moberg et al. Feb 2014 B2
8668672 Moberg et al. Mar 2014 B2
8674288 Hanson et al. Mar 2014 B2
8679060 Mernoe et al. Mar 2014 B2
8681010 Moberg et al. Mar 2014 B2
8690855 Alderete, Jr. et al. Apr 2014 B2
8708961 Field et al. Apr 2014 B2
8751237 Kubota Jun 2014 B2
8753326 Chong et al. Jun 2014 B2
8753331 Murphy Jun 2014 B2
8764707 Moberg et al. Jul 2014 B2
8764723 Chong et al. Jul 2014 B2
8771222 Kanderian, Jr. et al. Jul 2014 B2
8777896 Starkweather et al. Jul 2014 B2
8777924 Kanderian, Jr. et al. Jul 2014 B2
8777925 Patton Jul 2014 B2
8784369 Starkweather et al. Jul 2014 B2
8784370 Lebel et al. Jul 2014 B2
8790295 Sigg et al. Jul 2014 B1
8795224 Starkweather et al. Aug 2014 B2
8795231 Chong et al. Aug 2014 B2
8795260 Drew Aug 2014 B2
8801668 Ali et al. Aug 2014 B2
8810394 Kalpin Aug 2014 B2
9463280 Cabiri Oct 2016 B2
20020040208 Flaherty et al. Apr 2002 A1
20020043951 Moberg Apr 2002 A1
20020055711 Lavi et al. May 2002 A1
20030135159 Daily et al. Jul 2003 A1
20030160683 Blomquist Aug 2003 A1
20030171717 Farrugia et al. Sep 2003 A1
20030199825 Flaherty Oct 2003 A1
20040085215 Moberg et al. May 2004 A1
20040092873 Moberg May 2004 A1
20040116866 Gorman et al. Jun 2004 A1
20040260233 Garibotto et al. Dec 2004 A1
20050065472 Cindrich et al. Mar 2005 A1
20050070845 Faries et al. Mar 2005 A1
20050071487 Lu et al. Mar 2005 A1
20050171512 Flaherty Aug 2005 A1
20050177136 Miller Aug 2005 A1
20050197650 Sugimoto et al. Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050258714 Henderson et al. Nov 2005 A1
20060095014 Ethelfeld May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060173408 Wyrick Aug 2006 A1
20060173439 Thorne et al. Aug 2006 A1
20060184154 Moberg et al. Aug 2006 A1
20060229569 Lavi et al. Oct 2006 A1
20060264890 Moberg et al. Nov 2006 A1
20060283465 Nickel et al. Dec 2006 A1
20070021733 Hansen et al. Jan 2007 A1
20070049865 Radmer et al. Mar 2007 A1
20070118405 Campbell et al. May 2007 A1
20070149926 Moberg et al. Jun 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070191770 Moberg et al. Aug 2007 A1
20070219480 Kamen et al. Sep 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080033369 Kohlbrenner et al. Feb 2008 A1
20080051710 Moberg Feb 2008 A1
20080051711 Mounce et al. Feb 2008 A1
20080051727 Moberg et al. Feb 2008 A1
20080059133 Edwards et al. Mar 2008 A1
20080125700 Moberg et al. May 2008 A1
20080140006 Eskuri et al. Jun 2008 A1
20080140018 Enggaard et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080156476 Smisson Jul 2008 A1
20080167641 Hansen et al. Jul 2008 A1
20080188813 Miller et al. Aug 2008 A1
20080215006 Thorkild Sep 2008 A1
20080221522 Moberg et al. Sep 2008 A1
20080221523 Moberg et al. Sep 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080294143 Tanaka et al. Nov 2008 A1
20080306449 Kristensen et al. Dec 2008 A1
20080312601 Cane Dec 2008 A1
20080319416 Yodfat et al. Dec 2008 A1
20090054750 Jennewine Feb 2009 A1
20090076453 Mejlhede et al. Mar 2009 A1
20090088694 Carter et al. Apr 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093792 Gross et al. Apr 2009 A1
20090093793 Gross Apr 2009 A1
20090124977 Jensen May 2009 A1
20090149830 Spector Jun 2009 A1
20090182277 Carter Jul 2009 A1
20090234319 Marksteiner Sep 2009 A1
20090240240 Hines et al. Sep 2009 A1
20090253973 Bashan et al. Oct 2009 A1
20090259176 Yairi Oct 2009 A1
20090299397 Ruan et al. Dec 2009 A1
20090326509 Muse et al. Dec 2009 A1
20100030156 Beebe et al. Feb 2010 A1
20100030198 Beebe et al. Feb 2010 A1
20100037680 Moberg et al. Feb 2010 A1
20100049144 McConnell et al. Feb 2010 A1
20100057057 Hayter et al. Mar 2010 A1
20100076412 Rush et al. Mar 2010 A1
20100094255 Nycz et al. Apr 2010 A1
20100100076 Rush et al. Apr 2010 A1
20100100077 Rush et al. Apr 2010 A1
20100106098 Atterbury et al. Apr 2010 A1
20100121314 Iobbi May 2010 A1
20100137790 Yodfat Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100162548 Leidig Jul 2010 A1
20100168607 Miesel Jul 2010 A1
20100168683 Cabiri Jul 2010 A1
20100198157 Gyrn et al. Aug 2010 A1
20100204657 Yodfat et al. Aug 2010 A1
20100217192 Moberg et al. Aug 2010 A1
20100217193 Moberg et al. Aug 2010 A1
20100234830 Straessler et al. Sep 2010 A1
20100241065 Moberg et al. Sep 2010 A1
20100264931 Lindegger et al. Oct 2010 A1
20100274112 Hoss et al. Oct 2010 A1
20100274192 Mernoe Oct 2010 A1
20100276411 Hansen et al. Nov 2010 A1
20100280499 Yodfat et al. Nov 2010 A1
20100331826 Field et al. Dec 2010 A1
20110034900 Yodfat et al. Feb 2011 A1
20110054399 Chong et al. Mar 2011 A1
20110054400 Chong et al. Mar 2011 A1
20110060284 Harr Mar 2011 A1
20110119033 Moberg et al. May 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160666 Hanson et al. Jun 2011 A1
20110160669 Gyrn et al. Jun 2011 A1
20110172645 Moga et al. Jul 2011 A1
20110178472 Cabiri Jul 2011 A1
20110184342 Pesach et al. Jul 2011 A1
20110201998 Pongpairochana et al. Aug 2011 A1
20110224614 Moberg et al. Sep 2011 A1
20110233393 Hanson et al. Sep 2011 A1
20110238031 Adair et al. Sep 2011 A1
20110245773 Estes et al. Oct 2011 A1
20110264383 Moberg et al. Oct 2011 A1
20110270160 Mernoe Nov 2011 A1
20110282282 Lorenzen et al. Nov 2011 A1
20110295205 Kaufmann et al. Dec 2011 A1
20110313238 Reichenbach et al. Dec 2011 A1
20110313351 Kamen et al. Dec 2011 A1
20110319861 Wilk Dec 2011 A1
20110319919 Curry et al. Dec 2011 A1
20120004602 Hanson et al. Jan 2012 A1
20120010594 Holt et al. Jan 2012 A1
20120022499 Anderson et al. Jan 2012 A1
20120025995 Moberg et al. Feb 2012 A1
20120029431 Hwang et al. Feb 2012 A1
20120035546 Cabiri Feb 2012 A1
20120041364 Smith Feb 2012 A1
20120041370 Moberg et al. Feb 2012 A1
20120041414 Estes et al. Feb 2012 A1
20120071828 Tojo et al. Mar 2012 A1
20120096953 Bente, IV et al. Apr 2012 A1
20120096954 Vazquez et al. Apr 2012 A1
20120101436 Bazargan et al. Apr 2012 A1
20120108933 Liang et al. May 2012 A1
20120160033 Kow et al. Jun 2012 A1
20120165733 Bazargan et al. Jun 2012 A1
20120165780 Bazargan et al. Jun 2012 A1
20120215169 Moberg et al. Aug 2012 A1
20120215199 Moberg et al. Aug 2012 A1
20120226234 Bazargan et al. Sep 2012 A1
20120259282 Alderete, Jr. et al. Oct 2012 A1
20120310153 Moberg et al. Dec 2012 A1
20130068319 Plumptre et al. Mar 2013 A1
20130096509 Avery et al. Apr 2013 A1
20130133438 Kow et al. May 2013 A1
20130175192 Iio et al. Jul 2013 A1
20130218089 Davies et al. Aug 2013 A1
20130218092 Davies Aug 2013 A1
20130237953 Kow et al. Sep 2013 A1
20130245595 Kow et al. Sep 2013 A1
20130253419 Favreau Sep 2013 A1
20130253420 Favreau Sep 2013 A1
20130253421 Favreau Sep 2013 A1
20130331791 Gross et al. Dec 2013 A1
20140055073 Favreau Feb 2014 A1
20140055076 Favreau Feb 2014 A1
20140058349 Bazargan et al. Feb 2014 A1
20140083517 Moia et al. Mar 2014 A1
20140094755 Bazargan et al. Apr 2014 A1
20140128807 Moberg et al. May 2014 A1
20140128835 Moberg et al. May 2014 A1
20140135692 Alderete, Jr. et al. May 2014 A1
20140135694 Moberg et al. May 2014 A1
20140142499 Moberg et al. May 2014 A1
20140148784 Anderson May 2014 A1
20140148785 Moberg et al. May 2014 A1
20140163522 Alderete, Jr. et al. Jun 2014 A1
20140171881 Cabiri Jun 2014 A1
20140194819 Maule et al. Jul 2014 A1
20140207064 Yavorsky Jul 2014 A1
20140207065 Yavorsky Jul 2014 A1
20140207066 Yavorsky Jul 2014 A1
20140210631 Zavis Jul 2014 A1
20140213975 Clemente et al. Jul 2014 A1
20140236087 Alderete, Jr. et al. Aug 2014 A1
20140261758 Wlodarczyk et al. Sep 2014 A1
20140288511 Tan-Malecki et al. Sep 2014 A1
20150011976 Vouillamoz Jan 2015 A1
20160015910 Mukai et al. Jan 2016 A1
Foreign Referenced Citations (22)
Number Date Country
101868273 Oct 2010 CN
0401179 Dec 1990 EP
0744975 Dec 1996 EP
1666080 Jun 2006 EP
2060606 May 2009 EP
2345441 Jul 2011 EP
2454483 Aug 2015 EP
8911302 Nov 1989 WO
9009202 Aug 1990 WO
9521645 Aug 1995 WO
9632975 Oct 1996 WO
9721457 Jun 1997 WO
9733638 Sep 1997 WO
2007092618 Aug 2007 WO
2007130868 Nov 2007 WO
2008024810 Feb 2008 WO
2008024814 Feb 2008 WO
2008129549 Oct 2008 WO
2009081262 Jul 2009 WO
2011090955 Jul 2011 WO
2011113806 Sep 2011 WO
2012032411 Mar 2012 WO
Non-Patent Literature Citations (26)
Entry
U.S. Appl. No. 14/683,253 by Cabiri, filed Apr. 10, 2015.
Office Action dated May 18, 2015 in U.S. Appl. No. 13/429,942 by Cabiri.
U.S. Appl. No. 13/429,942 by Cabiri, filed Mar. 26, 2012.
U.S. Appl. No. 13/886,867 by Cabiri, filed May 3, 2013.
Int'l Search Report and Written Opinion dated Apr. 5, 2013 in Int'l Application No. PCT/US2012/050696.
Office Action dated Aug. 15, 2013 in U.S. Appl. No. 13/429,942 by Cabiri.
Office Action dated Jan. 16, 2014 in U.S. Appl. No. 13/429,942 by Cabiri.
Int'l Search Report and Written Opinion dated Jun. 30, 2014 in Int'l Application No. PCT/US2013/031598.
Int'l Search Report and Written Opinion dated Aug. 28, 2014 in Int'l Application No. PCT/US2014/035662.
Int'l Preliminary Report on Patentability dated Aug. 14, 2014 in Int'l Application No. PCT/US2012/050696.
U.S. Appl. No. 14/372,384 by Cabiri, filed Jul. 15, 2014.
Office Action dated Jan. 28, 2015 in U.S. Appl. No. 13/429,942 by Cabiri.
U.S. Appl. No. 14/593,041 by Cabiri, filed Jan. 9, 2015.
Office Action dated Apr. 19, 2016 in U.S. Appl. No. 14/372,384, by Cabiri.
Office Action dated May 17, 2016 in U.S. Appl. No. 13/886,867, by Cabiri.
Office Action dated Nov. 25, 2015 in U.S. Appl. No. 14/372,384 by Cabiri.
Office Action dated Oct. 28, 2015 in U.S. Appl. No. 13/429,942 by Cabiri.
Office Action dated Dec. 3, 2015 in CN Application No. 201280068544.0.
Office Action dated Feb. 24, 2016 in U.S. Appl. No. 13/429,942 by Cabiri.
Office Action dated Jun. 1, 2016 in CN Application No. 2013800274556.
Office Action dated Jun. 17, 2016 in CN Application No. 201280068544.0.
Office Action dated Feb. 15, 2017 in CN Application No. 2013800274556.
Office Action dated Jan. 17, 2017 in EP Application No. 13716886.
Office Action dated Sep. 8, 2017 is U.S. Appl. No. 15/510,846, by Aida.
Office Action dated Nov. 17, 2017 in U.S. Appl. No. 14/510,846, by Cabiri.
Office Action dated Nov. 14, 2017 in U.S. Appl. No. 14/593,041, by Cabiri.
Related Publications (1)
Number Date Country
20150224253 A1 Aug 2015 US
Continuations (2)
Number Date Country
Parent 14510846 Oct 2014 US
Child 14696644 US
Parent 13429942 Mar 2012 US
Child 14510846 US